Susanne Mohr

Title: Innovator Spotlight: Susanne Mohr and Her Contributions to Hepatitis B Virus Research

Introduction: Susanne Mohr is a notable inventor based in Basel, Switzerland, recognized for her innovative work in the field of molecular biology. With a focus on enhancing oligonucleotides, she has made significant contributions aimed at combating the challenges posed by the hepatitis B virus (HBV).

Latest Patents: Susanne holds a patent titled "Enhanced oligonucleotides for inhibiting RTEL1 expression." This groundbreaking invention encompasses antisense oligonucleotides that target the Regulator of Telomere Elongation Helicase 1 (RTEL1). The disclosure emphasizes the potential of these enhanced antisense oligonucleotides in both the treatment and prevention of HBV infections. Alongside this, pharmaceutical compositions and their applications are also described, reflecting the practical implications of her research.

Career Highlights: Currently, Susanne is employed at Hoffmann-La Roche Inc., a leading global healthcare company. Her work involves pioneering research focused on the interaction between oligonucleotides and viral infections, showcasing her expertise in both innovation and practical application within the pharmaceutical industry.

Collaborations: In her professional journey, Susanne collaborates closely with her coworker Natascha Hruschka, who is also a dedicated female scientist in the field. Together, they contribute to advancing research efforts and fostering a collaborative work environment that encourages the development of innovative solutions.

Conclusion: Susanne Mohr’s work signifies a remarkable intersection of innovation and biotechnology, particularly in the fight against hepatitis B virus. With her patent on enhanced oligonucleotides, she stands out as a valuable contributor to the scientific community. Her ongoing collaboration with peers like Natascha Hruschka highlights the importance of teamwork in driving forward the boundaries of medical research and innovation.